Several small molecules, peptides, and antibodies targeting the CXCR4 axis, such as plerixafor, BL-8040/BKT140, LY2510924, PF-06747143, BMS-936564, and NOX-A12, have shown promising results in leukemia, lymphoma, and myeloma [98]. This evidence concerns the gene CXCR4 and plasma cell myeloma.